加强百日咳研究和防控,维护公众疫苗接种信心&mdash;&mdash;关注效价指标不合格疫苗事件及其长期影响

姚开虎; 贾举

doi:10.7499/j.issn.1008-8830.2018.01.001

PDF(943 KB)

HTML

中国当代儿科杂志 ›› 2018, Vol. 20 ›› Issue (1) : 1-4. DOI: 10.7499/j.issn.1008-8830.2018.01.001

专家讲座

加强百日咳研究和防控,维护公众疫苗接种信心——关注效价指标不合格疫苗事件及其长期影响

姚开虎, 贾举

作者信息 +

Enhance research, prevention and control of pertussis for protecting public confidence in vaccination: focus on the adverse events of vaccine with insufficient potency and its long-term impacts

YAO Kai-Hu, JIA Ju

Author information +

文章历史 +

摘要

2017年11月3日，食品药品监管总局报告在药品抽样检验中检出两家公司的两个批次百白破疫苗效价指标不符合标准规定，可能影响免疫保护效果。当前国内百日咳存在病例增多趋势，并可能持续数年，这一变化易与疫苗效价不足事件联系起来，可能持久的影响公众对疫苗接种的积极性。百日咳再现的全球大环境、既往对国内百日咳的低估、检测方法的推广、对百日咳认识的变化、年长儿和成人百日咳的发现、流行菌株抗原性的变化等因素都可以导致今后百日咳病例明显增多。卫生科研和临床工作者应提高认识，科学评估疫苗效价不足事件对百日咳流行病学的影响，维护和提升公众疫苗接种信心。

Abstract

On November 3, 2017, the China Food and Drug Administration reported that the potency indexes of two batches of diphtheria-pertussis-tetanus vaccines produced by two companies did not reach the requirements. Insufficient potency could affect the protection effect of these vaccines immunization. Currently, pertussis cases have already showed an increasing trend in China and could last for several years. Such an increase could be linked to these adverse events of vaccine with insufficient potency, which could become an evidence to challenge or deny the effectiveness of vaccination, and brings a persistent inhibition of the public's acceptance for vaccination. The wider global context of pertussis resurgence, previous underestimate on the domestic pertussis, the promotion of detection methods, the change of knowledge about pertussis, the confirmation of pertussis in elder children and adults, the antigenicity variation of pertussis strains could lead to a significant increase of pertussis cases. Health researchers and clinical workers should raise awareness about these factors, and assess rationally the impact of vaccine titer deficiency on pertussis epidemiology for maintaining and promoting public confidence in vaccination.

导出引用

姚开虎, 贾举. 加强百日咳研究和防控,维护公众疫苗接种信心——关注效价指标不合格疫苗事件及其长期影响[J]. 中国当代儿科杂志. 2018, 20(1): 1-4 https://doi.org/10.7499/j.issn.1008-8830.2018.01.001

YAO Kai-Hu, JIA Ju. Enhance research, prevention and control of pertussis for protecting public confidence in vaccination: focus on the adverse events of vaccine with insufficient potency and its long-term impacts[J]. Chinese Journal of Contemporary Pediatrics. 2018, 20(1): 1-4 https://doi.org/10.7499/j.issn.1008-8830.2018.01.001

参考文献

[1] 国家食品药品监督管理总局. 食品药品监管总局新闻发言人介绍百白破疫苗效价指标不合格产品处置情况[EB/OL]. (2017-11-3)[2017-11-10]. http://www.sda.gov.cn/WS01/CL0050/216325.html.
[2] 中国疾病预防控制中心. 效价指标不合格的百白破疫苗相关问题解答[EB/OL]. (2017-11-5)[2017-11-10]. http://www.chinacdc.cn/yyrdgz/201711/t20171105_154664.html.
[3] 陈伟, 高志刚, 李永成, 等. 山东2016年非法经营疫苗案件对天津市儿童家长预防接种态度及行为影响调查[J]. 中国公共卫生, 2016, 32(7):881-884.
[4] Domenech de Cellès M, Magpantay FM, King AA, et al. The pertussis enigma:reconciling epidemiology, immunology and evolution[J]. Proc Biol Sci, 2016, 283(1822):20152309.
[5] 国家卫生计生委疾病预防控制局. 全国法定传染病疫情概况[EB/OL].[2017-11-14]. http://www.nhfpc.gov.cn/jkj/s3578/new_list.shtml.
[6] 刁连东, 徐爱强, 中华预防医学会. 百日咳免疫预防专家共识[J]. 中华流行病学杂志, 2011, 32(6):550-553.
[7] 黄辉, 邓莉, 肖飞, 等. 儿童百日咳发病特点及诊断中联合呼吸道病毒检测的临床意义分析[J]. 中华儿科杂志, 2017, 55(8):580-585.
[8] 许美, 邓继岿. 新生儿百日咳17例临床分析[J]. 临床儿科杂志, 2016, 34(9):667-669.
[9] 陈彦香, 王传清, 李乐, 等. 银川地区持续性咳嗽儿童百日咳博德特菌感染临床调查[J]. 临床儿科杂志, 2012, 30(9):862-865.
[10] 中华医学会儿科学分会感染学组, 《中华儿科杂志》编辑委员会. 中国儿童百日咳诊断及治疗建议[J]. 中华儿科杂志, 2017, 55(8):568-572.
[11] Yang Y, Yao K, Ma X, et al. Variation in Bordetella pertussis susceptibility to erythromycin and virulence-related genotype changes in China (1970-2014)[J]. PLoS One, 2015, 10(9):e0138941.
[12] 许红梅. 儿科医生应高度重视百日咳再现[J]. 中华儿科杂志, 2017, 55(8):564-567.
[13] 姚开虎, 邓继岿, 热夏提·达吾提. 百日咳诊断:现行标准的局限性和GPI建议[J]. 中国当代儿科杂志, 2016, 18(9):891-895.
[14] 黄海涛, 高志刚, 刘勇, 等. 天津市2005-2014年成年人百日咳流行特征及相关因素分析[J]. 中华流行病学杂志, 2016, 37(5):678-681.
[15] Diavatopoulos DA, Cummings CA, Schouls LM, et al. Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica[J]. PLoS Pathog, 2005, 1(4):e45.
[16] Mooi FR. Bordetella pertussis and vaccination:the persistence of a genetically monomorphic pathogen[J]. Infect Genet Evol, 2010, 10(1):36-49.
[17] Souder E, Vodzak J, Evangelista AT, et al. Antimicrobial susceptibility and molecular detection of pertactin-producing and pertactin-deficient Bordetella pertussis[J]. Pediatr Infect Dis J, 2017, 36(1):119-121.